Orgenesis to invest at least another US$1mln into Hemogenyx as part of latest collaboration deal
Orgenesis is to invest at least another US$1mln into HemoGenyx Pharmaceuticals PLC (LON:HEMO) after the biopharmas entered into a second collaboration deal in as many days.
Friday’s deal related to Hemogenyx’s advanced hematopoietic chimeras (AHC) – a new type of humanised mouse with a functional human immune system.
READ: Hemogenyx to receive US$1mln investment from Orgenesis
This latest agreement centres on Hemogenyx’s Human Postnatal Hemogenic Endothelial Cell (Hu-PHEC) technology.
Hu-PHEC is a cell replacement product candidate that is being developed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient.
“We are very pleased to announce this further collaboration with Orgenesis to rapidly develop and bring to the market our Hu-PHEC technology,” said chief executive and co-found Vladislav Sandler.
“The collaboration is a testament to the value of our Hu-PHEC based approach to drastically improving bone marrow transplants.”
Up to US$4mln over three years
As with Friday’s agreement, Orgenesis, possibly alongside other investors, will invest at least another US$1mln in Hemogenyx through a convertible loan, which can be converted into either Hemogenyx or Orgenesis stock.
Orgenesis will also have the option to invest up to a further US$1mln in Hemogenyx over the next three years. Overall, Orgenesis could invest up to US$4mln in Hemogenyx over the next three years.
In addition, the Nasdaq company has been granted a non-exclusive licence to use, market and sell Hemogenyx’s technology, patents and products.
Hemogenyx, which will still manufacture the products and supply them to Orgenesis, will take a 12% cut of any profits Orgenesis makes from selling its technology.
In a separate manufacturing and supply agreement to be inked at a later date, Orgenesis will be able to exclusively supply Hemogenyx products at the end of the clinical development stage.
Should the two fail to sign such an agreement, Hemogenyx will pay Orgenesis an amount equal to 4% of gross revenue derived from the sale of the respective Hemogenyx Products.
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/207524/orgenesis-to-invest-at-least-another-us1mln-into-hemogenyx-as-part-of-latest-collaboration-deal-207524.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).